Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

TransThera Sciences (Nanjing) Inc.

14 clinical trials

1 abstract

Clinical trial
A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast Cancers
Status: Active (not recruiting), Estimated PCD: 2023-01-31
Clinical trial
A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase I, Single-Center, Open-Label, 3-Way Crossover, Randomized Single Dose Study to Evaluate the Food Effect on the Pharmacokinetics of TT-00420 Tablet and to Determine the Relative Bioavailability of TT-00420 Tablet Versus TT-00420 Capsule in Adult Healthy Volunteers
Status: Completed, Estimated PCD: 2021-03-07
Clinical trial
A Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Oral TT-00420 (Tinengotinib) Tablets in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Prior Treatment of Chemotherapy and FGFR Inhibitor
Status: Recruiting, Estimated PCD: 2025-06-15
Clinical trial
A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) Tablet in Adult Patients With Advanced Cholangiocarcinoma
Status: Completed, Estimated PCD: 2024-02-28
Clinical trial
An Open Label, Multicenter Rollover Study for Continued Characterization of Safety and Tolerability of TT-00420 (Tinengotinib) Tablet Monotherapy in Adult Patients With Advanced Solid Tumors
Status:
Clinical trial
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib VS Physician's Choice in Subjects With FGFR-altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TT-00973-MS Tablets in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase I, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose and Multiple Dose Study of TT-00920 in Healthy Subjects
Status: Completed, Estimated PCD: 2022-06-06
Clinical trial
A Phase I, First-In-Human, Randomized, Double-blind, Placebo-controlled, Single-Ascending-Dose Study of TT-00920 in Healthy Subjects
Status: Completed, Estimated PCD: 2021-06-18
Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study of TT-00920 in Healthy Subjects
Status: Completed, Estimated PCD: 2021-11-30
Clinical trial
A Phase I, Multicenter, Open Label, and Dose-Escalation Study of TT-01488, Administered Orally in Adult Patients With B-Cell Malignancies
Status: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
A Phase I Study of the Safety, Tolerability, Pharmacokinetics Profile, and Preliminary Efficacy of TT-00434 in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-10-18
Clinical trial
A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2024-02-20
Abstract
Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial.
Org: Gabrail Cancer Center, TransThera Sciences (US), Inc., TransThera Sciences (Nanjing) Inc., CRC Oncology Corp,